Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tegaserod. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 known ✓ | Q13639 | 1/20 | 0.67 |
| ▸ | HTR1A | P08908 | 5/20 | 0.67 |
| ▸ | HTR2C | P28335 | 5/20 | 0.67 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.67 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.67 |
| ▸ | DRD2 | P14416 | 2/20 | 0.67 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.67 |
| ▸ | DRD4 | P21917 | 2/20 | 0.67 |
| ▸ | HTR2A | P28223 | 2/20 | 0.67 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.67 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.67 |
| ▸ | DRD3 | P35462 | 2/20 | 0.67 |
| ▸ | HTR2B | P41595 | 2/20 | 0.67 |
| ▸ | HTR3A | P46098 | 2/20 | 0.67 |
| ▸ | HTR5A | P47898 | 2/20 | 0.67 |
| ▸ | HTR6 | P50406 | 2/20 | 0.67 |
| ▸ | MLNR | O43193 | 1/20 | 0.67 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.67 |
| ▸ | PGR | P06401 | 1/20 | 0.67 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tegaserod SCHEMBL774764 | 1.00 | HTR1A (0.67) | HTR1AHTR2CADRB1ADRB3DRD2 | |
| Tegaserod SCHEMBL16464 | 1.00 | HTR1A (0.67) | HTR1AHTR2CADRB1ADRB3DRD2 | |
| Tegaserod SCHEMBL5180106 | 0.99 | HTR1A (0.66) | HTR1AHTR2CADRB1ADRB3DRD2 | |
| Tegaserod SCHEMBL4797293 | 0.99 | HTR1A (0.66) | HTR1AHTR2CADRB1ADRB3DRD2 | |
| Tegaserod SCHEMBL4797289 | 0.99 | HTR1A (0.66) | HTR1AHTR2CADRB1ADRB3DRD2 | |
| Tegaserod SCHEMBL4961312 | 0.99 | HTR1A (0.66) | HTR1AHTR2CADRB1ADRB3DRD2 | |
| Tegaserod SCHEMBL3635467 | 0.99 | HTR1A (0.66) | HTR1AHTR2CADRB1ADRB3DRD2 | |
| Tegaserod SCHEMBL5652626 | 0.99 | HTR1A (0.66) | HTR1AHTR2CADRB1ADRB3DRD2 | |
| Tegaserod SCHEMBL4961318 | 0.99 | HTR1A (0.66) | HTR1AHTR2CADRB1ADRB3DRD2 | |
| Tegaserod SCHEMBL4773941 | 0.99 | HTR1A (0.66) | HTR1AHTR2CADRB1ADRB3DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158092-A1 | New Oral Formulation | NOVARTIS AG (CH) | 2013-06-20 | — | — | US | claimed |
| US-20120071537-A1 | New Oral Formulation | DE BRUIJN KAREL (FR) | 2012-03-22 | — | — | US | claimed |
| US-20080075773-A1 | New Oral Formulation | DE BRUIJN KAREL | 2008-03-27 | — | — | US | claimed |
| WO-2007119109-A2 | PROCESSES FOR PREPARING TEGASEROD MALEATE AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT | MEDICHEM, S.A. (US) | 2007-10-25 | — | — | WO | claimed |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-09-14 | — | — | US | disclosed |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-09-14 | — | — | US | disclosed |
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-02-16 | — | — | US | disclosed |
| US-20210283265-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-09-16 | — | — | US | disclosed |
| US-20210284629-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-09-16 | — | — | US | disclosed |
| US-20210238226-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-08-05 | — | — | US | disclosed |
| US-20210228723-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-07-29 | — | — | US | disclosed |
| US-20130158092-A1 | New Oral Formulation | NOVARTIS AG (CH) | 2013-06-20 | — | — | US | disclosed |
| CN-1589906-A | New oral formulation for 5-HT4 agonists or antagonists | NOVARTIS AG (CH) | 2005-03-09 | — | — | CN | disclosed |
| WO-2005014544-A1 | STABLE MODIFICATIONS OF TEGASEROD HYDROGEN MALEATE | NOVARTIS AG (CH) | 2005-02-17 | — | — | WO | disclosed |
| EP-1488788-A1 | Pharmaceutical combinations and their use in treating gastrointestinal disorders | Novartis AG (CH) | 2004-12-22 | — | — | EP | disclosed |
| WO-2004105795-A1 | PHARMACEUTICAL COMBINATIONS OF A PROTON PUMP INHIBITOR AND A COMPOUND WHICH MODIFIES GASTROINTESTINAL MOTILITY | ALTANA PHARMA AG (DE) | 2004-12-09 | — | — | WO | disclosed |
| US-20040092511-A1 | Pharmaceutical combinations and their use in treating gastrointestinal and abdominal viscera disorders | BILLSTEIN STEPHAN ANTHONY (US) | 2004-05-13 | — | — | US | disclosed |
| US-20030236183-A1 | Oral formulation | DE BRUIJN KAREL (FR) | 2003-12-25 | — | — | US | disclosed |
| EP-1321142-A1 | Solid pharmaceutical composition for oral administration of Tegaserod | Novartis AG (CH) | 2003-06-25 | — | — | EP | disclosed |
| CN-1323200-A | 5HT4Novel oral formulations of agonists or antagonists | NOVARTIS AG (CH) | 2001-11-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238226-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ATXN2L, ATXN2, ATXN10 | HTR4 780/4885HTR1A 350/4885HTR2C 595/4885 |
| US-20120071537-A1 | New Oral Formulation | ABCG2, SI, SLC10A2 | HTR4 1787/4885HTR1A 1441/4885HTR2C 1357/4885 |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, CBL, UBQLN2 | HTR4 2446/4885HTR1A 2937/4885HTR2C 2974/4885 |
| US-20080075773-A1 | New Oral Formulation | ABCG2, SI, SLC10A2 | HTR4 1787/4885HTR1A 1441/4885HTR2C 1357/4885 |
| US-20210283265-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, CBL, UBQLN2 | HTR4 2446/4885HTR1A 2937/4885HTR2C 2974/4885 |
| US-20030236183-A1 | Oral formulation | SLC10A2, ABCG2, SI | HTR4 2386/4885HTR1A 1993/4885HTR2C 2216/4885 |
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | CYFIP2, TPX2, ATXN2 | HTR4 721/4885HTR1A 731/4885HTR2C 437/4885 |
| US-20040092511-A1 | Pharmaceutical combinations and their use in treating gastrointestinal and abdominal viscera disorders | MLNR, HTR3D, HTR1D | HTR4 4/4885HTR1A 8/4885HTR2C 28/4885 |
| US-20130158092-A1 | New Oral Formulation | ABCG2, SI, SLC10A2 | HTR4 1787/4885HTR1A 1441/4885HTR2C 1357/4885 |
| US-20210228723-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ZFX, F13B, GRN | HTR4 2178/4885HTR1A 2316/4885HTR2C 2485/4885 |
| US-20210284629-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, UBQLN2, UBTF | HTR4 2457/4885HTR1A 3037/4885HTR2C 2795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.